Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850394 | 0.95 | S1PR1 (0.42) | DAOTYRS1PR1KIF11PDE2A | |
| SCHEMBL16284397 | 0.85 | TAAR1 (0.41) | DAOKIF11PDE2ACYP3A4CYP2D6 | |
| SCHEMBL14850100 | 0.84 | TAAR1 (0.40) | DAOS1PR1KIF11PDE2ACYP3A4 | |
| SCHEMBL28677421 | 0.82 | TYR (0.41) | TYRS1PR1CYP3A4CYP2D6MEN1 | |
| SCHEMBL19304136 | 0.79 | IDO1 (0.51) | DAOTYRPDE2ACYP3A4IDO1 | |
| SCHEMBL102128 | 0.79 | CES2 (0.43) | DAOKIF11PDE2ACYP3A4CYP2D6 | |
| SCHEMBL13349970 | 0.79 | DAO (0.51) | DAOPDE2APOLQCES2IDO1 | |
| SCHEMBL9797614 | 0.78 | TYR (0.61) | TYRPDE2ACYP3A4IDO1MEN1 | |
| SCHEMBL21312970 | 0.78 | CYP3A4 (0.40) | TYRS1PR1CYP3A4CYP2D6POLQ | |
| SCHEMBL8764873 | 0.78 | L3MBTL1 (0.43) | TYRL3MBTL1IDO1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8796275-B2 | Anti-malarial compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | DAO 3313/4885TYR 2054/4885S1PR1 543/4885 |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | DAO 3313/4885TYR 2054/4885S1PR1 543/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | DAO 3313/4885TYR 2054/4885S1PR1 543/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | DAO 4461/4885TYR 1739/4885S1PR1 407/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | DAO 4461/4885TYR 1739/4885S1PR1 407/4885 |
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | DAO 2655/4885TYR 33/4885S1PR1 1003/4885 |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | AADAC, ME2, HTRA2 | DAO 2655/4885TYR 33/4885S1PR1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.